Artigos com autorizações de acesso público - Daniel Botelho CostaSaiba mais
6 artigos não disponíveis publicamente
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
H Yasuda, S Kobayashi, DB Costa
The lancet oncology 13 (1), e23-e31, 2012
Autorizações: US National Institutes of Health
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II …
M Yanagita, AJ Redig, CP Paweletz, SE Dahlberg, A O'Connell, N Feeney, ...
Clinical Cancer Research 22 (24), 6010-6020, 2016
Autorizações: US National Institutes of Health
Molecular testing in lung cancer: the time is now
H Cheng, X Xu, DB Costa, CA Powell, B Halmos
Current oncology reports 12, 335-348, 2010
Autorizações: US National Institutes of Health
ALK inhibitors: plateauing systemic and intracranial activity?
DB Costa
The Lancet Oncology 17 (4), 404-406, 2016
Autorizações: US National Institutes of Health
Trastuzumab Deruxtecan in Non–Small-Cell Lung Cancer
H Viray, D Rangachari, DB Costa
The New England journal of medicine 386 (18), 1769, 2022
Autorizações: US National Institutes of Health
EGFR-Directed Therapy in Lung Cancer
SY Kim, DB Costa, D Shibahara, S Kobayashi, B Halmos
Elements in Molecular Oncology, 2023
Autorizações: US Department of Defense, US National Institutes of Health
108 artigos disponíveis publicamente
Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer
EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ...
New England Journal of Medicine 363 (18), 1693-1703, 2010
Autorizações: US National Institutes of Health
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
AT Shaw, BY Yeap, M Mino-Kenudson, SR Digumarthy, DB Costa, ...
Journal of clinical oncology 27 (26), 4247-4253, 2009
Autorizações: US National Institutes of Health
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ...
New England Journal of Medicine 371 (21), 1963-1971, 2014
Autorizações: US National Institutes of Health, Swedish Research Council
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ...
The lancet oncology 13 (10), 1011-1019, 2012
Autorizações: US National Institutes of Health
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
S Koyama, EA Akbay, YY Li, GS Herter-Sprie, KA Buczkowski, ...
Nature communications 7 (1), 10501, 2016
Autorizações: US National Institutes of Health, German Research Foundation, Damon Runyon …
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ...
The lancet oncology 12 (11), 1004-1012, 2011
Autorizações: US National Institutes of Health
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
DB Costa, AT Shaw, SHI Ou, BJ Solomon, GJ Riely, MJ Ahn, C Zhou, ...
Journal of Clinical Oncology 33 (17), 1881-1888, 2015
Autorizações: US National Institutes of Health
Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–positive lung cancer and acquired resistance to osimertinib
GR Oxnard, Y Hu, KF Mileham, H Husain, DB Costa, P Tracy, N Feeney, ...
JAMA oncology 4 (11), 1527-1534, 2018
Autorizações: US Department of Defense, US National Institutes of Health, Damon Runyon …
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
MJ Niederst, LV Sequist, JT Poirier, CH Mermel, EL Lockerman, ...
Nature communications 6 (1), 6377, 2015
Autorizações: US National Institutes of Health
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer
H Yasuda, E Park, CH Yun, NJ Sng, AR Lucena-Araujo, WL Yeo, ...
Science translational medicine 5 (216), 216ra177-216ra177, 2013
Autorizações: US National Institutes of Health
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor pathway
KSH Nguyen, S Kobayashi, DB Costa
Clinical lung cancer 10 (4), 281-289, 2009
Autorizações: US National Institutes of Health
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Z Chen, K Cheng, Z Walton, Y Wang, H Ebi, T Shimamura, Y Liu, ...
Nature 483 (7391), 613-617, 2012
Autorizações: US National Institutes of Health
Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers
D Rangachari, N Yamaguchi, PA VanderLaan, E Folch, A Mahadevan, ...
Lung cancer 88 (1), 108-111, 2015
Autorizações: US National Institutes of Health
Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib …
S Heon, BY Yeap, GJ Britt, DB Costa, MS Rabin, DM Jackman, ...
Clinical cancer research 16 (23), 5873-5882, 2010
Autorizações: US National Institutes of Health
As informações de publicação e financiamento são determinadas automaticamente por um programa de computador